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clear.   In   order   to  unravel   the   role   of   lncRNAs   associated  with  B­cell   precursor  Acute
Lymphoblastic Leukemia (BCP­ALL) subtypes, we performed transcriptome sequencing and
DNA methylation array across 82 BCP­ALL samples from three molecular subtypes (DUX4,
Ph­like,  and Near Haploid or High Hyperdiploidy).  Unsupervised clustering of  BCP­ALL
samples  on  the  basis  of   their   lncRNAs on  transcriptome and DNA methylation  profiles
revealed   robust   clusters   separating   three   molecular   subtypes.   Using   extensive
computational   analysis,   we   developed   a   comprehensive   catalog   of   1235   aberrantly
dysregulated BCP­ALL subtype­specific lncRNAs with altered expression and methylation
patterns from three subtypes of BCP­ALL. By analyzing the co­expression of subtype­specific
lncRNAs   and   protein­coding   genes,   we   inferred   key  molecular   processes   in   BCP­ALL
subtypes.  A   strong   correlation  was   identified  between   the  DUX4   specific   lncRNAs  and
activation of TGF­  and Hippo signaling pathways. Similarly, Ph­like specific lncRNAs wereβ
correlated with genes involved in activation of PI3K­AKT, mTOR, and JAK­STAT signaling
pathways.   Interestingly,   the   relapse­specific   differentially   expressed   lncRNAs   correlated
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progression.  LncRNAs does not  code for proteins  and represent  around 70% of human
transcripts. Recently, there are a number of studies used lncRNAs expression profile in the


























.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/365429doi: bioRxiv preprint first posted online Jul. 9, 2018; 
INTRODUCTION
B­cell Precursor Acute Lymphoblastic Leukemia (BCP­ALL) is the most prevalent disease in
children  and   affects   also  adults.  Despite   improvements   in   treatment   regimens   such   as














Hyperdiploid   (NH­HeH)   (51–67   chromosomes)   subtype  (9,10)  is   a   common   subtype,
comprising   30%   of   all   pediatric   BCP­ALL.   These   subtypes   are   clinically   relevant  with
distinct   gene   expression   profile   and   have   been   widely   studied   in   the   recent   past.
Nevertheless,  we  are   far   from complete  understanding  of  BCP­ALL   subtypes  and   their
heterogeneity and its associated molecular mechanisms, which pose a major challenge for
improving diagnosis and therapy. Recent studies have suggested that long non­coding RNAs
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(13).   LncRNAs  expression  has   been   reported  as  highly   tissue­specific   even   though   the
expression   abundance   is   generally   lower   compared   to   protein­coding   genes  (14).  The
expression specificity has been extended to a wide variety of physiological and pathological
mechanisms   like   cancer   development   and  Pluripotency  (15).   LncRNAs   can   act   either
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Unique lncRNAs expression profiles characterize BCP-ALL subtypes
To identify  BCP­ALL subtype­specific   lncRNAs,  we analysed  transcriptome profiles   from
paired initial diagnosis (ID) and relapse (REL) samples of 26 pediatric and 22 adult BCP­
ALL  patients   lacking  known  chromosomal   translocations   like  BCR­ABL.  Based  on  DNA
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DUX4 subtype showed robust separation compared to the remaining samples implying a
subtype­specific lncRNAs signatures.













Identification and inferred functions of lncRNAs associated with molecular subtypes
of BCP-ALL




specific lncRNAs (see materials and methods). Expression of both  cis  and  trans  PC genes
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Ph­like 260 170 (383) 261  173 (383)








activation   of   key   signalling   pathways   involved   in   proliferation,   apoptosis,   and
differentiation in leukemia (Table S2). For example, in the cis based analysis, we identified
a strong correlation between DUX4 specific lncRNAs and genes involved in the TGF­beta,
Hippo,  and  P53  signalling  pathways   (Fig  2A,  Table  S2).  Whereas,   the  Ph­like   specific
lncRNAs were correlated with genes involved in JAK­STAT, mTOR, and PIK3­AKT signalling
pathways   (Fig   2B,   Table   S2).  The  trans  based   analysis   revealed   same   vital   signalling
pathways in DUX4 subtype (Fig S3A­B, Table S2), whereas in Ph­like subtype we identified
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genes such as  TGFB2,  ITGA6,  CD22,  and  RARA  genes,  which were enriched  in vital
molecular pathways in BCP­ALL.
However,   there  were   no   significant   pathways   identified  within  NH­HeH   subtype.   The






PC   based   functional   enrichment   analysis   (Fig   2C).  Whereas,   in   Ph­like   subtype,   we
identified 60% (9 out of 15) same pathways between DE PC based and DE lncRNAs based
functional   enrichment  analysis   (Table  S2  and  Fig  2D).  However,  we   identified  Ph­like
specific   lncRNAs   to  be  more   strongly  correlated  with  genes   involved   in  key   signalling
pathways than Ph­like specific protein­coding genes. For example, we identified mTOR and
PI3K­AKT exclusively in the Ph­like specific lncRNAs based analysis. Together, our analyses
highlight   important   functions   of   BCP­ALL   subtype­specific   lncRNAs   whose   expression
correlates tightly with that of cancer­related oncogenes.
Relapse-specific lncRNAs driving BCP-ALL progression
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The  putative  molecular   functions  of   relapse­specific   lncRNAs  were   identified  using   the
previously mentioned guilt­by­association approach. Relapse­specific   lncRNAs within Ph­






S3).   These   results   indicate   that   relapse­specific  markers   from  DUX4   subtype  may   be
functionally engaged in metabolic and signalling pathways.





=   60,021,   Table   S4)   associated   with   7,160   lncRNAs   was   compared   with   CpG   sites
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0;  P­value  <= 0.05) and hyper­methylated (methylation difference value > 0.2;  P­value
<= 0.05) CpGs associated with lncRNAs in each subtype (see materials and method). The
hierarchical   clustering   of   differentially   methylated   (DM)   lncRNAs   showed   distinct
methylation patterns of each subtype, concordant with the DE lncRNAs signature (Fig 4B­D,
Table S4). In the DUX4 and NH­HeH subtypes the number of hypo­methylated lncRNAs
(differential  methylation   value  <  0,  P­value  <= 0.05)  were   higher   compared   to   the




like   subtype  has   shown a  higher  degree  of  hyper­methylated  DM  lncRNAs   than  hypo­
methylated DM lncRNAs.  The  list  of   subtype­specific  DM lncRNAs  from three  subtypes
contained previously defined epigenetically altered lncRNAs from other cancer types, for
example,  we  observed   the  oncogenic   lncRNAs  LINC00312  (40),  PVT1,   and  TCL6  (41),
which are differentially methylated in at least one of the three subtypes. Together, this data
illustrates that epigenetically altered lncRNAs within three BCP­ALL subtypes.
Correlation between differentially expressed and differentially methylated lncRNAs
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AC003075.4 ­0.31 0.004 1.43 ­1.26
DUX4
AC099754.1 ­0.32 0.002 ­1.74 3.2
AC104655.3 ­0.26 0.017 ­2.27 2.07
CACNA1C­AS1 ­0.45 2.03E­05 1.97 ­1.62
CTB­25B13.9 ­0.26 0.016 ­1.73 1.46
IGF2­AS ­0.24 0.028 ­1.33 4.95
LINC01006 ­0.39 0.001 ­2.06 2.53
PVT1 ­0.40 0.001 ­2.13 1.15
RGMB­AS1 ­0.26 0.0193 ­1.48 5.96
RP11­125B21.2 ­0.35 0.001 ­1.75 4.11
RP11­138M12.1 ­0.70 5.21E­13 ­5.98 3.77
RP11­367G6.3 ­0.30 0.004 1.98 ­1.63
RP11­624M8.1 ­0.50 1.34E­06 ­3.34 4.13
RP11­789C17.3 ­0.36 0.001 ­2.27 3.2
SERTAD4­AS1 ­0.25 0.0232 ­1.98 1.79
LINC01006 ­0.38 0.0003 1.44 ­1.56
Ph­like
RP11­138M12.1 ­0.70 5.21E­13 2.06 ­1.44
RP11­305F18.1 ­0.64 5.36E­11 1.76 ­2.08
AC099754.1 ­0.33 0.002 1.21 ­1.36
ACVR2B­AS1 ­0.36 0.0009 2.18 ­1.75
LINC00996 ­0.39 0.0003 ­1.56 2.11
ERICH1­AS1 ­0.40 0.0006 ­1.82 2.21
DIO3OS ­0.31 0.0037 ­1.76 4.05
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corresponding   subtypes.  DM: Differentially  methylated.  The significance   is  calculated
based on Pearson correlation rate and two ­tailed P­value <= 0.05.
Of   these  23   putative   epigenetically   facilitated   lncRNAs,   15  were   related   to   the  DUX4
subgroup (Fig 5A) including the novel lncRNAs, R11­138M12.1 and RP11­624M8.1. These
were   significantly   hypo­methylated   at   their   promoter   region   and   transcriptionally   up­
regulated in the DUX4 subgroup (Pearson correlation coefficient = ­0.69; P­value = 5.1E­
13  for  R11­138M12.1;  Pearson correlation coefficient  =  ­0.50;  P­value  = 1.36E­06  for
RP11­624M8.1;   Fig  5B   and  5C).   In   the  Ph­like   subtype,  we  observed  7   lncRNAs  with
promoter  methylation (Fig  5D);  interestingly,  the   same  lncRNA  R11­138M12.1  showed
significant hypermethylation at the promoter region and a concordant down­regulation in
the   Ph­like   subgroup   (Fig   5E).   Besides   these   novel   lncRNAs,   we   identified   lncRNAs
previously   reported   in   the   context   of  different   cancers   from our   epigenetically   altered
results. The lncRNAs  PVT1  (Pearson correlation coefficient =  ­0.40,  2­tailed  P­value  <=
0.001),  and  DIO3OS  (42)  (Pearson correlation   coefficient  =  ­0.31,  2­tailed  P­value  =
0.0037)    are   examples,  which  we   observed   in   the  DUX4   and  NH­HeH   subtype  with
significant anti­correlation (2­tailed P­value <= 0.01) to its expression level. Around 46%
(n = 512) of  DM subtype­specific   lncRNAs are  localized  in the  intronic  and  intergenic
genomic   regions.  We   next   aimed   to   investigate   whether   these   lncRNAs   regions   has
chromatin markers encoded within their genomic location. Recent human genome­wide
chromatin marker study  (43) has provided us with a rich resource to identify chromatin
markers.  Genome­wide  mapping   of   B­lymphocyte   cell   line   by   searching   for   epigenetic
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RP11­398B16.2,  RP11­689B22.2,  CTC­458I2.2  and  LINC00880  were DE expressed, with a
significant  negative   correlation  between  DNA methylation  and  expression   levels   in   the
DUX4 subtype (Table 5) . 













RP11­134O21.1 2.54 ­1.56 ­0.63 1.9E­010 Enhancer
Intron
RP11­398B16.2 2.08 ­1.85 ­0.47 0.0007 Insulator
RP11­689B22.2 1.52 ­3.37 ­0.47 0.008 Enhancer
CTC­458I2.2 ­1.16 3.38 ­0.42 0.0001 Enhancer
LINC00880 ­1.45 2.23 ­0.25 0.02 Enhancer Intergenic
The significance is calculated based on Pearson correlation rate and two ­tailed P­value
<=   0.05.   The   lncRNAs   are   promoter   differentially   methylated   and   differentially
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78 protein­coding genes located in their  cis  region, out of these 33 protein­coding genes
have   shown a   significant  up­regulated   and  down­regulated   expression  pattern   in   their
corresponding subtypes (Table 6). 








CTD­2231H16.1 ­1.6803385981 PLEKHG4B 2.4840131576
DUX4
RP11­80H8.4 ­4.8712973818 CHST2 5.021248353
IGF2­AS ­1.5149692084 IGF2 6.7074586227
RP11­332H18.4 1.7840373497 TBX2 5.6459057649
RP11­332H18.4 1.7840373497 TBX4 1.5056957579
RP11­624M8.1 ­3.3400278742 HEY2 3.5653881965
CTB­25B13.9 ­1.7341024339 REEP6 1.0135168425
RGMB­AS1 ­1.4711332705 RGMB 4.4287098777
AC073316.1 ­2.1346425435 SDK1 4.2539854375
CTB­35F21.2 ­3.3996007483 CXXC5 1.5322350503
CTB­35F21.2 ­3.5262894443 PSD2 2.0348265047
AC099754.1 ­1.7432607805 LRRC3B 3.2956570803
AC078883.4 ­3.4089445499 CORO1C 0.797282079
AC078883.4 ­3.4089445499 ITGA6 3.2489394471
RP11­314O13.1 ­1.5432811428 CDYL2 1.7070802978
RP3­455J7.4 ­3.0695619042 CREG1 1.5618184051
RP11­125B21.2 ­1.749750681 VLDLR 4.2858349208
RP11­676J12.8 ­1.8927665898 GLOD4 0.6471353534
LINC00114 3.4320004844 ETS2 ­0.7176247124
RP11­367G6.3 1.9798401851 THBS4 ­1.5796823436
CTC­458I2.2 3.3822300323 CTGF ­1.892559675
RP11­69I8.3 2.355315514 AHR ­2.4815111685
RP11­293A21.1 ­3.6963992484 STIM2 2.487452138 NH­HeH
LINC00114 ­2.9731205546 ETS2 0.9908037963
ACVR2B­AS1 2.3094716973 ACVR2B ­2.4697071313 Ph­like
AGAP1­IT1 2.0926102582 AGAP1 ­2.9857451706
RP11­69I8.3 ­3.1689478827 CTGF 1.8492946882
LINC00996 ­1.553999019 GIMAP8 1.4145369937
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CTB­79E8.2 ­2.2285747372 NEURL1B 1.1469246971
AL133493.2 2.0838061516 PCBP3 ­3.0795988736
RP11­420G6.4 ­2.4300037457 SERPINB1 0.5848645847
The   table   represents   hypo­methylated   and   hyper   methylated   lncRNAs   from   three
subtypes elevating and diminishing the expression of the protein­coding genes localized
at their cis regions. The PC genes differentially up and down regulated in the respective










Although   previous   studies   have   demonstrated   the   involvement   of   lncRNAs   in   acute
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significant insights and advances over other studies: it provides the most comprehensive
novel  datasets  so   far   for  BCP­ALL subtypes,  a  resource of  subtype­specific  and relapse­
specific lncRNAs, potential lncRNAs functions and uncovers their epigenetic alterations of
the BCP­ALL subtypes. We identified 1235 DE subtype­specific lncRNAs dysregulated in at
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resistance   in   solid   cancer  (54).  Within   the  DUX4   subtype,  we   identified   up­regulated







the subtype­specific  and relapse­specific   lncRNAs associated with activation of  signaling
pathways and metabolic pathways that are associated with leukemogenesis including TGF­
Beta,   hippo,   P53,   and   JAK­STAT,   cytokine­cytokine   receptor,   endocytosis,  mTOR   and
metabolic   pathways.   Characterization   of   the   lncRNAs   involved   in   this   pathway   may
potentially reveal novel targets in molecular therapies.
The functional insights of relapse­specific and subtype­specific lncRNAs revealed biological
relevance   to  BCP­ALL   subtypes   including   cell   cycle   functions,   signal   transduction,   cell
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previous   studies   emphasizing   the   strengths   of   the   employed   guilt­by­association.   For
example, lncRNA  AC002454.1, which we associated to the PIK3­AKT pathway in Ph­like
subtype, was recently reported to regulate cyclin­dependent kinase (CDK6) to participate in
cell   cycle   disorder  (55).   The  CDK6  gene   appears   to   be   frequently   dysregulated   in
hematopoietic malignancies  (39)  and is hence attributed a critical role in tumorigenesis,








associated   with   TGF­beta   pathway,   including   the   antisense  RP11­224019.2,   with   a
significant positive correlation to the TGFB gene. Recently, there are a number of lncRNAs
documented to be associated with TGFß signalling pathway, including MEG3 regulating the
TGFB2   pathway   in   breast   cancer  (58).   However,   lncRNAs   associated  with   the   TGFß
pathway in BCP­ALL subtypes have not been reported. The co­expression of RP11­224019.2
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with poor prognosis in lung cancer (54). However, the LUCAT1 has not yet been reported in
















































.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/365429doi: bioRxiv preprint first posted online Jul. 9, 2018; 
onco­lncRNAs, which are promoter methylated in one of the three subtypes. The lncRNA,
PVT1  was reported for its MYC activity  (64,65)  and as oncogenic lncRNA with multiple







promoter   region   that   are   significantly   correlated  with   their   diminished   and   increased
expression in respective subtypes. In addition to that, we have identified 33 epigenetically
co­regulated   oncogenes   localized   in   the  cis  regions   of   hypo­methylated   and   hyper­
methylated  lncRNAs   from   three   subtypes.   Interestingly,   the   oncogene   associated  with
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by   routine   diagnostic   workup   (BCR­ABL,  MLL   translocations,   ETV6­RUNX1)   from   26




obtained  from all  patients.  The  studies  were  approved by  the  ethics  board of  Charité,
Berlin.
Overview of RNA-seq and DNA methylation array data
To generate transcriptome profiles of patient samples, mRNA was isolated by using Trizol
reagent   (Life   Technologies,   Grand   Island,   NY)   procedure   from   the   bone   marrow
mononuclear cells (MNCs) of the ID and REL samples. The paired­end RNA sequencing was
done on Illumina HiSeq4000 platform (multiplexing) in the high throughput sequencing
core  facility,  German Cancer  Research Center,  Heidelberg,  Germany.  The RNA­Seq was
performed by  using   six   samples  per   lane,  which   resulted   in  an  average  of  64  Million
mapped   paired   reads   per   sample.   For  methylation,   genomic   DNA  was   isolated   using
unstranded Allprep extraction (Qiagen, Hilden, Germany) from the bone marrow of same
patients   (ID   and   REL   samples)   was   then   hybridized   onto   an   Illumina   Infinium
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transcriptome construction and gene­level   counts   for  each  sample  were  obtained using





Sample clustering and differential expression analysis for subtype- specific and 
relapse-specific lncRNAs
We performed PCA using the  prcomp  R function on 13,860 lncRNAs from RNA­seq and








subtypes.  LIMMA voom  leveraged  the   sample   imbalances  and  confounder  (patient  and
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subtype separately.  The significant DE genes were assigned based on the p­value < 0.01   
and   Fold   change   of  >= +­1.5.   The   lncRNAs   from  GENCODE   version   19   (equivalent
Ensembl GRCh37) were used as reference annotation. The heatmaps and correlation based
(Spearman  method)  hierarchical   clustering  of  DE   lncRNAs  were  performed  on   z­score
transformed LIMMA normalized gene expression values using the R Bioconductor package
ComplexHeatmap.
Differential methylation data analysis
The ID and REL samples from the same patients have been assayed with the Illumina 450k
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body.   The   gene  body  was   defined   if   the  CpGs  were   annotated   in   exonic,   intronic   or
transcription termination site (TTS). The regions mapped to lncRNAs were then used for
analysis.  The   significantly  differentially  hyper­methylated   (Methylation  difference  value
>= 0.2;  P­value  <= 0.05) and hypo­methylated (Methylation difference value =< 0;  P­
value  <=   0.05)   regions   were   used   for   further   analysis.   The   intronic   and   intergenic
differentially methylated (DM) lncRNAs were then mapped using  'BedTools' with the B­













The individual  cis  and  trans  genes for each DE lncRNAs were located within a genomic
window of 100 kb and greater >100kb respectively. From each dataset, we then computed
the   pairwise   expression   correlation   using   Pearson   correlation   method   between   each
lncRNAs and its cis and trans coding gene. The significantly co­expressed PC genes (Pearson
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Fig   S2:   BCP­ALL   subtype­specific   differentially   expressed   lncRNAs.   (A­C)  The
hierarchical clustering representing lncRNAs clustering and expression differences of the






using   the   respective  DE   lncRNA signature.  The  BCP­ALL   samples  box   representing   the
number of samples within each subtypes and versus (vs) the other samples used as control
group in DE analysis. (D) The overlap between DE subtype specific lncRNAs from three
subtypes   versus   public   list   of   dysregulated   lncRNAs   from   12   different   cancer   types
comprehensive cancer genome (CGC)
Fig  S3:  Comparison  of  molecular  pathways   from cis  and   trans  based  analysis  on
subtype­specific DE lncRNAs. (A) Molecular pathway analysis from functional enrichment


























.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/365429doi: bioRxiv preprint first posted online Jul. 9, 2018; 
(B) The molecular pathways overlapped between  cis  (< 100 kb proximity) and    trans  (>
100 kb) based functional enrichment analysis in the DUX4 subtype. (C) Molecular pathway
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(A)  PCA  plot   constructed   from expression  FPKM values   of   lncRNAs   from 82  BCP­ALL
samples obtained from RNA­seq. Each point represents a BCP­ALL sample. DUX4, Ph­like,
NH­HeH,   LH subtype and others are represented by orange, rose, blue, green and gray
respectively.   (B)  Heatmap   illustrates   hireachial   clustering  DE   subtype­specific   lncRNAs
(absolute   Fold   change   >=   +­   1.5,  P­value   <=   0.01)   signature   based   on   z­score
transformed LIMMA normalized expression values on 930 subtype­specific lncRNAs from
DUX4 (n = 450),  Ph­like (n = 193), and NH­HeH (n = 287) subtypes.  (C) The venn
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KEGG pathways or biological functions presented in the heatmaps and barplots show with
P­value <= 0.05 and > 2 genes involved in each pathways. The hypergeometric p­values   
are obtained  from GeneSCF for   the pathways.  CAMs :  Cell  adhesion molecules,  CML :
Chronic myeloid leukemia, AML : Acute myeloid leukemia.
Fig 3: Relapse­specific DE lncRNAs from BCP­ALL subtypes.














methylated (DM) CGID's   associated  with  434  lncRNAs  in  DUX4 subtype.   In   the  DUX4
subtype, we identified 328 (76%) differentially hypo­methylated and 106 (25%) hyper­
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(A)   The   promoter  methylated   lncRNAs  with   significant   negative   correlation  with   DE
expression profile from the DUX4 subtypes. (B­C) Two representative examples of hypo­
methylated lncRNAs with increased expression profile from DUX4 subtype. LncRNAs, RP11­
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= 0.0057 ),  RGMB­AS1  (DNA methylation value = ­1.47,  P­value = 0.007), and  RP11­
125B21.2  (DNA  methylation   value  =   ­1.75,  P­value  =   0.007)   and   its   corresponding
significatly up­regulated  cis  oncogenes,  CHT2  (absolute log fold change = 5.021, FDR =
2.39E­08), IGF2 (absolute log fold change = 6.71, FDR = 41.412E­15), TBX (absolute log
fold change =5.64, FDR = 3.97E­13), and RGMB (absolute log fold change = 4.42, FDR =




08),  LINC00996  (DNA methylation value = ­1.55,  P­value = 0.02 ),  CTB­79E8.2  ( DNA
methylation value = ­2.22,  P­value = 0.009 ),  RP11­420G6.4  (DNA methylation value =
­2.43,  P­value  = 0.004 )  and  its  corresponding  significatly  up­regulated  cis  oncogenes,
CTGF  ( absolute log fold change = 1.85, = 0.02 ),  GIMAP8  (absolute log fold change =
1.14, FDR = 0.004),  NEURLB (absolute log fold change = 1.14, FDR = 0.09),  SERPINB1
(absolute log fold change = 1.63, FDR = 0.0004) within Ph­like subtype.  (C) The upper
panel   of   boxplot   represents   the   DNA   methylated   lncRNAs,   the   boxplot   below   that
represents   their  cis  ocogenes  which  are  up­regulated   in  NH­HeH subytpe.  The  barplot
shows representative examples of hypo­methylated lncRNAs, LINC00114 (DNA methylation
value = ­2.97, P­value = 0.0003),  RP11­293A21.1  (DNA methylation value = ­3.69, P­
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FDR = 6.42E­10) within NH­HeH subtype. False discovery rate: FDR
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